NO20090135L - Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid - Google Patents

Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid

Info

Publication number
NO20090135L
NO20090135L NO20090135A NO20090135A NO20090135L NO 20090135 L NO20090135 L NO 20090135L NO 20090135 A NO20090135 A NO 20090135A NO 20090135 A NO20090135 A NO 20090135A NO 20090135 L NO20090135 L NO 20090135L
Authority
NO
Norway
Prior art keywords
methyl
indol
hydroxy
phenyl
ethyl
Prior art date
Application number
NO20090135A
Other languages
English (en)
Norwegian (no)
Inventor
Joel Slade
Piotr Karpinski
Dimitris Papoutsakis
Joginder S Bajwa
Frank Stowasser
Murat Acemoglu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090135(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20090135L publication Critical patent/NO20090135L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
NO20090135A 2006-06-12 2009-01-09 Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid NO20090135L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80451706P 2006-06-12 2006-06-12
US88322407P 2007-01-03 2007-01-03
PCT/US2007/070561 WO2007146716A2 (en) 2006-06-12 2007-06-07 Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Publications (1)

Publication Number Publication Date
NO20090135L true NO20090135L (no) 2009-03-12

Family

ID=38832679

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090135A NO20090135L (no) 2006-06-12 2009-01-09 Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid

Country Status (29)

Country Link
US (1) US7989494B2 (it)
EP (2) EP2409967A1 (it)
JP (3) JP2009540006A (it)
KR (4) KR20090015968A (it)
CN (1) CN102584673B (it)
AR (1) AR061297A1 (it)
AU (1) AU2007257881B2 (it)
BR (1) BRPI0712993A2 (it)
CA (1) CA2650263A1 (it)
CL (1) CL2007001689A1 (it)
CR (1) CR10440A (it)
EA (1) EA017984B1 (it)
EC (1) ECSP088976A (it)
GE (1) GEP20115175B (it)
GT (1) GT200800280A (it)
IL (1) IL195015A (it)
MA (1) MA30511B1 (it)
ME (1) ME00529B (it)
MX (1) MX2008015900A (it)
MY (1) MY149337A (it)
NI (1) NI200800306A (it)
NO (1) NO20090135L (it)
PE (1) PE20080852A1 (it)
PH (2) PH12012501724A1 (it)
SM (1) SMP200900001B (it)
TN (1) TNSN08495A1 (it)
TW (2) TWI515179B (it)
UY (1) UY30406A1 (it)
WO (1) WO2007146716A2 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007257962B2 (en) * 2006-06-12 2011-06-23 Secura Bio Inc. Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
BRPI0806341A2 (pt) * 2007-01-10 2011-09-06 Novartis Ag formulações de inibidores de desacetilase
WO2017032281A1 (zh) * 2015-08-21 2017-03-02 苏州晶云药物科技有限公司 帕比司他乳酸盐的新晶型
CN106866492B (zh) * 2015-12-10 2021-11-26 江苏豪森药业集团有限公司 帕比司他乳酸盐晶型ii及其制备方法和用途
CN106866491B (zh) * 2015-12-10 2021-12-10 江苏豪森药业集团有限公司 帕比司他乳酸盐晶型ⅰ及其制备方法和用途
WO2018092151A1 (en) * 2016-11-21 2018-05-24 Msn Laboratories Private Limited, R&D Center Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof
WO2018163114A1 (en) * 2017-03-10 2018-09-13 Shilpa Medicare Limited Amorphous panobinostat and its lactate salt
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CA3150303A1 (en) * 2019-08-20 2021-02-25 Ono Pharmaceutical Co., Ltd. Salt and crystal form of compound having agonistic activity to s1p5 receptor
GB201913121D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913122D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
MX2023004799A (es) * 2020-10-28 2023-05-10 Viracta Subsidiary Inc Formas de estado solido de inhibidor de hdac.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1443967B1 (en) * 2001-11-06 2007-01-24 Novartis AG Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
WO2003048774A1 (en) 2001-12-07 2003-06-12 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
CA2526908A1 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
JP2007501775A (ja) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
AU2004273615B2 (en) 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
AU2007257962B2 (en) 2006-06-12 2011-06-23 Secura Bio Inc. Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide

Also Published As

Publication number Publication date
UY30406A1 (es) 2008-01-31
CR10440A (es) 2011-08-22
MA30511B1 (fr) 2009-06-01
PE20080852A1 (es) 2008-08-19
PH12012501724A1 (en) 2014-05-12
MX2008015900A (es) 2009-03-06
KR20140142335A (ko) 2014-12-11
ECSP088976A (es) 2009-01-30
WO2007146716A3 (en) 2009-07-30
AU2007257881A1 (en) 2007-12-21
BRPI0712993A2 (pt) 2012-04-17
CN102584673B (zh) 2014-08-06
IL195015A0 (en) 2009-08-03
EA017984B1 (ru) 2013-04-30
TWI515179B (zh) 2016-01-01
SMP200900001B (it) 2010-03-01
TW201441190A (zh) 2014-11-01
IL195015A (en) 2014-03-31
EP2086930A2 (en) 2009-08-12
GEP20115175B (en) 2011-03-10
ME00529B (me) 2011-10-10
CN102584673A (zh) 2012-07-18
WO2007146716A2 (en) 2007-12-21
CA2650263A1 (en) 2007-12-21
TNSN08495A1 (en) 2010-04-14
TWI453196B (zh) 2014-09-21
KR20150082690A (ko) 2015-07-15
EA200802383A1 (ru) 2010-02-26
JP2009540006A (ja) 2009-11-19
CL2007001689A1 (es) 2008-05-16
SMAP200900001A (it) 2009-01-14
KR20090015968A (ko) 2009-02-12
PH12012501725A1 (en) 2015-07-06
JP2015164968A (ja) 2015-09-17
KR20160032264A (ko) 2016-03-23
EP2409967A1 (en) 2012-01-25
GT200800280A (es) 2015-11-24
US7989494B2 (en) 2011-08-02
US20090192210A1 (en) 2009-07-30
MY149337A (en) 2013-08-30
AU2007257881B2 (en) 2011-06-16
NI200800306A (es) 2012-02-01
TW200815344A (en) 2008-04-01
AR061297A1 (es) 2008-08-20
JP2013139476A (ja) 2013-07-18

Similar Documents

Publication Publication Date Title
NO20090135L (no) Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid
NO20090128L (no) Salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid
NO20090136L (no) Fremgangsmate for fremstilling av salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-1ln-dol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
NO20090137L (no) Fremgangsmate for fremstilling av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid og startmaterialer derav
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
HK1132509A (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
CU20080237A7 (es) Polimorfos de n-hidroxi-3-[4-[[[2-metil-1h-indol-3-il)etil]amino]metil]fenil]2e-2-propenamida

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application